newsfilter
← Latest News
GlobeNewswire·

Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position

Patient dosing commenced in the DReAMzz Phase 2 dose-optimization study of IHL-42X in obstructive sleep apneaU.S. composition and methods of treatment patent granted covering IHL-42X with baseline expiry in